Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedPointe expands sales force with Innovex

Executive Summary

Quintiles contract sales subsidiary Innovex will recruit and train 120 sales reps for MedPointe. The additional force increases MedPointe's total sales reps to 300 and expands the number of primary care doctors called on from 28,000 to 50,000. Training will focus on the antihistamine nasal spray Astelin and cold products Ryna/Tussi; recruitment should be completed by March. Medpointe, lead by former Warner-Lambert exec Anthony Wild, acquired Carter-Wallace's prescription business in October (1"The Pink Sheet" May 14, 2001, p. 13)...

You may also be interested in...



Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild

A successor to the anti-epileptic Felbatol is among the development projects for Carter-Wallace's healthcare unit following its acquisition by an investment firm run by former Warner-Lambert exec Anthony Wild.

Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer

Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.

Shuren Gives Peek Behind Curtain With 3 Lessons FDA’s Device Center Learned During Pandemic

CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel